Perspectives of people living with HIV‐1 on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation‐effectiveness study

INTRODUCTION: The CUSTOMIZE hybrid III implementation‐effectiveness study evaluated implementation of once‐monthly long‐acting (LA) cabotegravir + rilpivirine in diverse US healthcare settings. Here, we report patient participant perspectives after 12 months in CUSTOMIZE. METHODS: CUSTOMIZE was a ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Garris, Cindy P., Czarnogorski, Maggie, Dalessandro, Marybeth, D'Amico, Ronald, Nwafor, Toyin, Williams, Will, Merrill, Deanna, Wang, YuanYuan, Stassek, Larissa, Wohlfeiler, Michael B., Sinclair, Gary I., Mena, Leandro A., Thedinger, Blair, Flamm, Jason A., Benson, Paul, Spreen, William R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468562/
https://www.ncbi.nlm.nih.gov/pubmed/36097674
http://dx.doi.org/10.1002/jia2.26006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468562/
https://www.ncbi.nlm.nih.gov/pubmed/36097674
http://dx.doi.org/10.1002/jia2.26006

Ejemplares similares